Associates Iv L P Venrock P... Net Worth

The estimated Net Worth of Associates Iv L P Venrock P... is at least $262 Tisíc dollars as of 14 August 2018. Associates P owns over 529,370 units of Bellerophon Therapeutics Inc stock worth over $261,647 and over the last 6 years Associates sold BLPH stock worth over $0.

Associates P BLPH stock SEC Form 4 insiders trading

Associates has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Associates bought 529,370 units of BLPH stock worth $344,091 on 14 August 2018.

The largest trade Associates's ever made was buying 529,370 units of Bellerophon Therapeutics Inc stock on 14 August 2018 worth over $344,091. On average, Associates trades about 529,370 units every 0 days since 2018. As of 14 August 2018 Associates still owns at least 6,541,163 units of Bellerophon Therapeutics Inc stock.

You can see the complete history of Associates P stock trades at the bottom of the page.

Insiders trading at Bellerophon Therapeutics Inc

Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein a Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.

What does Bellerophon Therapeutics Inc do?

bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

Complete history of Associates P stock trades at Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc executives and stock owners

Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Fabian Tenenbaum,
  Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director
• Peter Fernandes,
  Chief Regulatory and Safety Officer
• Assaf Korner,
  Chief Financial Officer, Secretary
• Peter Fernandes M. Pharm,
  Interim Principal Exec. Officer, Chief Regulatory & Safety Officer
• Martin Dekker,
  Vice President - Engineering and Manufacturing
• Jonathan Peacock,
  Chairman of the Board
• Crispin Teufel,
  Independent Director
• Mary Cloyd,
  Independent Director
• Naseem Amin,
  Independent Director
• Andre Moura,
  Independent Director
• Theodore Wang,
  Independent Director
• Scott Bruder,
  Independent Director
• Matthew Bennett,
  Independent Director
• Wassim Fares,
  Chief Medical Officer.
• Amy Edmonds,
  Vice President - Clinical Operations and Administration
• Parag Shah,
  Vice President - Business Operations
• Dr. Edwin L. Parsley,
  Acting Chief Medical Officer
• Dr. Parag Suresh Shah,
  VP of Bus. Operations
• Nicholas Laccona,
  Principal Financial & Accounting Officer and Sec.
• Cross Border Opportunities ...,
  
• Megan Schoeps,
  Principal Financial Officer
• Matthew S. Holt,
  Director
• Deborah Quinn,
  Chief Medical Officer
• Adam Weinstein,
  Director
• Daniel Tasse,
  Director
• Mountain Investments Ii, Ll...,
  
• Life Science Opportunities ...,
  
• Associates Iv L P Venrock M...,
  
• Associates Iv L P Venrock H...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Shah Nimi...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Venrock H...,
  
• Jens Luehring,
  Director
• Venture Fund Vi Lparch Vent...,
  
• Martin Meglasson,
  Chief Scientific Officer
• Mountain Investments Ii, Ll...,
  
• Manesh Naidu,
  Chief Business Officer
• Robert Nelsen,
  Director
• North America, Inc. Linde,
  10% owner
• Amit Agrawal,
  Chief Operating Officer
• David Abrams,
  Treasurer
• R Scott Huennekens,
  Director
• Reinilde Heyrman,
  Chief Clinical Dev. Officer
• Associates Iv L Pvenrock En...,
  
• Life Science Opportunities ...,
  
• Nicholas Laccona,
  FINANCIAL OFFICER, (PFO & PAO)
• Capital Management Lp Puiss...,
  
• Life Science Opportunities ...,
  
• Bobae Kim,
  VP Reg. Affairs & Quality